Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients

@inproceedings{Botti2017ProgrammedDL,
  title={Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients},
  author={Gerardo Botti and Francesca Collina and Giosu{\`e} Scognamiglio and Federica Rao and Valentina Peluso and Rossella De Cecio and Michela Piezzo and Gabriella Landi and Michelino De Laurentiis and Monica Cantile and Maurizio Di Bonito},
  booktitle={International journal of molecular sciences},
  year={2017}
}
Triple Negative Breast Cancers (TNBC) subtype is an aggressive disease with poor clinical outcome. The only treatment available is surgery followed by chemotherapy or radiotherapy. Programmed death-ligand 1 (PD-L1) is a trans-membrane protein expressed on a wide variety of cells including immune cells, epithelial and vascular endothelial cells. Recently, PD-1/PD-L1 pathway signaling was described as an adaptive immune resistance mechanism enacted by the tumor cells to evade the immune response… CONTINUE READING